RDHLRedHill Biopharma Ltd.
RDHL
RedHill Biopharma Ltd.7,174
Mkt Cap
$5.55MVolume
17,760.0052W High
$3.3152W Low
$0.7101PE Ratio
-0.01RDHL Fundamentals
Price
$1.09Prev Close
$1.09Open
$1.1050D MA
$0.8888Beta
0.90Avg. Volume
26,614.35EPS (Annual)
-$0.1008P/B
-0.57Rev/Employee
$22,174.54$0.353
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease RedHill's RHB-204 Demonstrates Comparable MAP Killing...
PR Newswire·1d ago
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights PR Newswire TEL AVIV...
PR Newswire·4d ago
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity...
PR Newswire·9d ago
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) DelveInsight
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight H. pylori Infections Market in the 6MM to Observe...
PR Newswire·2mo ago
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) DelveInsight
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight Biliary Tract Cancer Market is Predicted to Exhibit...
PR Newswire·2mo ago
Joint U.S. Commercialization of RedHill's Talicia Commences
Joint U.S. Commercialization of RedHill's Talicia Commences Joint U.S. Commercialization of RedHill's Talicia Commences PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, Feb. 25, 2026 The full sales...
PR Newswire·2mo ago
What's Going On With Redhill Biopharma Stock On Tuesday?
RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.read more...
Benzinga·4mo ago
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side...
PR Newswire·4mo ago
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells PR...
PR Newswire·5mo ago
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement PR...
PR Newswire·5mo ago
<
1
2
...
>